Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...
8don MSN
2 beaten-down artificial intelligence (AI) stocks for contrarian investors to consider buying
These aren't for the faint of heart.
Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results